Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing personalized treatments for neuropsychiatric conditions. The company utilizes a proprietary Precision Psychiatry Platform that integrates neurocognitive assessments, electroencephalography, wearable device data, and genomic samples to discover brain-based biomarkers for patient stratification. Its clinical pipeline includes seven assets targeting major depressive disorder, bipolar depression, treatment-resistant depression, schizophrenia, and Parkinson’s disease. The most advanced program, ALTO-207, is a fixed-dose combination of pramipexole and ondansetron designed to address treatment-resistant depression by mitigating dose-limiting adverse events. Alto Neuroscience was founded in 2019 and acquired ALTO-207 from Chase Therapeutics Corporation in May 2025. The company develops internal software tools, including Spectra, TechCheck, and Altoscope, to support biomarker data collection and analysis.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage altoneuroscience.com
Sector Healthcare IR page investors.altoneuroscience.com/overview/default.aspx
Tags
precision psychiatry, neuropsychiatric disorders, major depressive disorder, bipolar depression, treatment-resistant depression, schizophrenia, parkinson's disease, biomarker discovery, electroencephalography, genomics, central nervous system, clinical-stage, ALTO-207, CTC-501, Spectra, TechCheck, Altoscope, Chase Therapeutics Corporation
Press page —

Metrics

Valuation  
Market cap $ 1.059B
Market cap (USD) $ 1.059B
P/E -10.81
PEG —
P/BV 3.57
P/S —
P/OCF -13.38
P/FCF -13.29
Dividend yield —
Turnover / mcap —
Returns  
ROE -41.8%
ROI -37.7%
ROIC -29.6%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 4.5%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 13
Quality score -69.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue — — 0 0 210K
Net profit -63.238M -61.431M -36.305M -27.71M -9.187M
Free cash flow -51.793M -49.499M -33.918M -21.126M -9.942M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 17.8 4.23 — — —
Price performance 12m 3.21 — — — —

Filed figures

Figure Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) — 0.00 0.00 585,000
Borrowings, non-current (USD) — 9.86M 10.3M 16.2M
Lease liabilities (USD) — 125,000 5.39M 4.97M
Cash and deposits (USD) 48.3M 82.5M 168M 176M
Right-of-use assets (USD) — 0.00 5.04M 4.26M
Net debt (borrowings + leases - cash) (USD) — -72.6M -153M -155M
Cash flow detail
Operating cash flow (USD) — -33.4M -47.4M -51.8M
Purchases of property, plant and equipment (USD) — -470,000 -2.08M -24,000
Change in payables (cash effect) (USD) — -632,000 516,000 221,000
Interest paid (cash effect) (USD) — -912,000 -999,000 -1.66M
Share-based compensation (USD) — 2.89M 7.63M 8.11M
Free cash flow (OCF - PPE - intangibles) (USD) — -33.9M -49.5M -51.8M
Income detail
Research and development expense (USD) — 30.3M 47M 45.6M
Reported May 14, 2024 Mar 20, 2025 Mar 20, 2025 Mar 16, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

– Phase 1 study results on the modified-release formulation of ALTO-207 and blinded PACE-1 safety data expected by early 2027; data expected to inform Phase 3 planning –

– Strengthened balance sheet and extended cash runway with $100 million financing; cash position of $319.8 million expected to fund planned operations through 2030 –

MOUNTAIN VIEW, Calif., November 10, 2026 – (BUSINESS WIRE) – Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended September 30, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates.

“During the third quarter, we continued to advance our clinical programs and strengthened our financial position ahead of a milestone-rich 2027,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience.

September 9, 2026

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will participate in the following upcoming investor conferences:

  • H.C. Wainwright 28th Annual Global Healthcare Conference, September 14-16, 2026

    • Format: Fireside chat and one-on-one meetings
    • Presentation Date & Time: September 14, 2026, 9:30 am ET
    • Location: New York, NY and virtual
  • Baird’s 2026 Global Healthcare Conference, September 15, 2026

    • Format: Company presentation and one-on-one meetings
    • Presentation Date & Time: September 15, 2026, 9:40 am ET
    • Location: New York, NY
  • TD Cowen’s 6th Annual Novel Mechanisms in Neuropsychiatry Summit, September 23, 2026

    • Format: Fireside chat
    • Presentation Date & Time: September 23, 2026, 3 pm ET
    • Location: Virtual

The presentations will be accessible via a live webcast on the Events and Presentations page in the Investors section of Alto’s website and a replay will be available following the presentation.

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.

Availability of Information on Alto’s Website

Alto routinely uses its investor relations website to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website.

Investor Contact:
[email protected]

Media Contact:
[email protected]

Source: Alto Neuroscience, Inc.

View All News

Link to Alto Neuroscience main page

Contact Us

650 Castro Street, Suite 450
Mountain View, CA 94041

Follow us on LinkedIn Follow us on X

Company

Science

Investors

Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Alto Neuroscience, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Alto Neuroscience to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert OptionsInvestor Alert Options *

News
Events & Presentations
Quarterly Reports
Annual Reports
SEC Filings
End of Day Stock Quote

Submit Sign up

Unsubscribe

Email Alert Sign Up Confirmation

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

© 2026 Alto Neuroscience, Inc. All rights reserved

August 27, 2026

Expanded role reflects leadership across finance, corporate strategy, and business development

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026.

Mr. Smith will continue to lead Alto’s finance function and oversee corporate strategy and business development, reporting to Amit Etkin, M.D., Ph.D., Alto’s founder, chief executive officer and chair of the board of directors.

Mr. Smith joined Alto in 2021 as chief business officer and has served as chief financial officer since 2022. During his tenure, he has led Alto’s corporate development and capital strategy, including the company’s initial public offering, the acquisition of ALTO-207 in May 2025 and subsequent financings supporting the program’s development.

“Nick has been an exceptional partner in building Alto and has played a central role in the strategic and financial actions that have positioned the company for its next stage,” said Dr. Etkin. “This promotion recognizes the breadth of his leadership and formalizes the role he already plays as we advance ALTO-207 and the broader pipeline.”

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto's Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto's clinical-stage pipeline includes novel drug candidates in treatment-resistant depression, major depressive disorder, bipolar depression, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X .

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding Alto’s advancement of its clinical development programs. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including those described under “Risk Factors” in Alto’s most recent filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alto expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as required by law.

Investor Contact:
[email protected]

Media Contact:
[email protected]

Source: Alto Neuroscience, Inc.

View All News

Link to Alto Neuroscience main page

Contact Us

650 Castro Street, Suite 450
Mountain View, CA 94041

Follow us on LinkedIn Follow us on X

Company

Science

Investors

Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Alto Neuroscience, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Alto Neuroscience to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert OptionsInvestor Alert Options *

News
Events & Presentations
Quarterly Reports
Annual Reports
SEC Filings
End of Day Stock Quote

Submit Sign up

Unsubscribe

Email Alert Sign Up Confirmation

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

© 2026 Alto Neuroscience, Inc. All rights reserved

Prompts

Alto Neuroscience, Inc. (ticker ANRO), listed in United States.

ETFs Holding Alto Neuroscience, Inc.

ETF Weight in ETF Shares Market value As of
PSIL 4.70% 71,847 $ 1.79M Nov 17, 2026
VFMO 0.10% 56,726 $ 2.007M Aug 31, 2026
RESM 0.04% 54 $ 1,425.06 Jun 30, 2026
MSSM 0.01% 1,213 $ 42.916K Aug 31, 2026
DCOR 0.00% 26,782 $ 820.065K Nov 12, 2026
DFAS 0.00% 17,506 $ 536.034K Nov 12, 2026
DFAC 0.00% 30,640 $ 938.197K Nov 12, 2026
DFUS 0.00% 6,888 $ 210.911K Nov 12, 2026
DXUV 0.00% 1,295 $ 39.653K Nov 12, 2026